40 results
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
15 May 20
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
7:05am
on our, expenses, supply chain, strategic partners, research and development costs, clinical trials and employees; our expectation about timing … of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
10 Aug 20
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
7:07am
and operations, including on our expenses, supply chain, strategic partners, research and development costs, clinical trials and employees; our expectation … , or supply chain disruptions caused by the coronavirus pandemic; risks associated with current and potential future healthcare reforms; risks
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
12 Nov 20
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
7:40am
, supply chain, strategic partners, research and development costs, clinical trials and employees; our expectation about timing and execution … associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; risks associated with current
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
10 May 21
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
7:05am
of COVID-19 on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research and development … and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; risks associated with current and potential future
8-K
EX-99.1
STOK
Stoke Therapeutics Inc
5 Feb 21
Regulation FD Disclosure
4:27pm
impact of COVID-19 on our business, financial condition and operations, including on our expenses, supply chain, strategic partners, research … are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused
8-K
EX-99.1
htxzacr65
11 Jan 21
Results of Operations and Financial Condition
8:01am
8-K
EX-99.1
zfwdkw p7yy4mc27aor
20 Nov 20
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
4:08pm
8-K
EX-99.1
qeht33 le
17 Aug 20
Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors
7:46am
8-K
gckc2w6bdstp0mcy
9 Jul 20
Regulation FD Disclosure
6:06am
8-K
EX-99.1
cn2da8kqrl i3
9 Jul 20
Regulation FD Disclosure
6:06am
8-K
EX-99.1
5wdh72eqsb
12 May 20
Regulation FD Disclosure
10:50am
8-K
EX-99.1
a7oxno0xz4cl5 lk9
23 Mar 20
STOKE THERAPEUTICS Reports FULL YEAR 2019 financial results and provides business updateS
8:00am
8-K
EX-99.1
8at9apuf jo20o
9 Mar 21
Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates
7:30am
8-K
EX-99.1
hzton j00gow2a5ci7
10 Jan 22
Entry into a Material Definitive Agreement
7:01am